2-methyl-N-(1-phenyl-2-pyridin-2-ylethyl)propan-2-amine | 104617-00-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-methyl-N-(1-phenyl-2-pyridin-2-ylethyl)propan-2-amine
• CAS: 104617-00-7
• 化学式: C₁₇H₂₂N₂
• 分子量: 254.375
• InChiKey: PIXZATMZBCTCTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  正丁基锂 、 2-methyl-N-(1-phenyl-2-pyridin-2-ylethyl)propan-2-amine 生成 lithium;tert-butyl-(1-phenyl-2-pyridin-2-ylethyl)azanide
  参考文献：
  名称：

  CLIFFE, I. A.;CROSSLEY, R.;SHEPHERD, R. G., SYNTHESIS, BRD, 1985, N 12, 1138-1140

  摘要：

  DOI：
• 作为产物：
  描述：

  苯甲醛 在 甲醇 作用下， 反应 9.5h， 生成 2-methyl-N-(1-phenyl-2-pyridin-2-ylethyl)propan-2-amine
  参考文献：
  名称：

  Sterically Hindered Lithium Dialkylamides; A Novel Synthesis of Lithium Dialkylamides fromN-t-Alkyl-N-benzylideneamines and the Isolation of Highly Hindereds-Alkyl-t-alkylamines

  摘要：

  本文描述了从亚胺1和有机锂试剂方便合成锂胺，以及相关的高度阻碍的二烷基胺3的分离。

  DOI：

  10.1055/s-1985-31452

文献信息

• 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
  申请人：FISONS CORPORATION

  公开号：EP0540318A1

  公开（公告）日：1993-05-05

  Compounds of formula I, wherein    A represents C=C, S or O;    Q represents a 5- or 6-membered unsaturated heterocyclic ring having a nitrogen atom in the position adjacent to the point of attachment, 0-3 further heteroatoms selected from N, O and S, and substituents R⁶ and R⁷;    R¹ represents H or C₁₋₆ alkyl;    R² represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₆ cycloalkyl or NH₂CH₂CO-; in addition, R¹ and R² taken together may form a C₃₋₅ alkylene chain;    R³ represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl;    R⁴ and R⁵ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl or NR⁸R⁹;    R⁶ and R⁷ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl, C₁₋₆ hydroxyalkyl, amidino, CONH₂ or NR⁸R⁹;    in addition, R⁶ and R⁷ may independently represent O when substituted on N;    R⁸ and R⁹ independently represent H or C₁₋₆ alkyl;    with various provisos;    and pharmaceutically acceptable derivatives thereof;    are useful as pharmaceuticals, in particular in the treatment of neurological disorders.

  式 I 的化合物、 其中 A 代表 C=C、S 或 O； Q 代表 5 或 6 元不饱和杂环，该杂环在邻近连接点的位置有一个氮原子，0-3 个选自 N、O 和 S 的杂原子，以及取代基 R⁶ 和 R⁷； R¹ 代表 H 或 C₁₋₆ 烷基； R² 代表 H、C₁₋₆ 烷基、C₃₋₆ 烯基、C₃₋₆ 炔基、C₃₋₆ 环烷基或 NH₂CH₂CO-；此外，R¹ 和 R² 合在一起可形成 C₃₋₅亚烷基链； R³ 代表 H、C₁₋₆ 烷基、C₃₋₆ 烯基、C₃₋₆ 炔基； R⁴ 和 R⁵ 各自代表 H、OH、C₁₋₆ 烷氧基、C₁₋₆ 烷基、卤素、三氟甲基或 NR⁸R⁹； R⁶ 和 R⁷ 独立地代表 H、OH、C₁₋₆ 烷氧基、C₁₋₆ 烷基、卤素、三氟甲基、C₁₋₆ 羟烷基、脒基、CONH₂ 或 NR⁸R⁹； 此外，当 R⁶ 和 R⁷ 被 N 取代时，可独立地代表 O； R⁸ 和 R⁹ 独立地代表 H 或 C₁₋₆ 烷基； 具有各种但书； 及其药学上可接受的衍生物； 可用作药物，特别是用于治疗神经系统疾病。
• Prodrugs of lanicemine and their method of use
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US11358935B2

  公开（公告）日：2022-06-14

  Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的Lanicemine原药，可通过释放Lanicemine来治疗与NMDA受体活性失调有关的疾病，如抑郁症和抑郁障碍，Lanicemine原药对肝脏代谢的稳定性增强，通过口服给药进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放Lanicemine。
• 2-HETEROCYCLICETHYLAMINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：FISONS CORPORATION

  公开号：EP0612314A1

  公开（公告）日：1994-08-31
• 2-PYRAZINYLETHYLAMINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
  申请人：Astra Aktiebolag

  公开号：EP0612314B1

  公开（公告）日：1999-12-29
• PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20200299238A1

  公开（公告）日：2020-09-24

  Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.